Search research articles
Contact Us
Filters
Showing results (241-250 of 302) with videos related to
Page
of 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
Ramesh K Ramanathan, Merrill J Egorin, Julie L Eiseman, et al.
British Journal of Cancer
|
July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Annals of Surgical Oncology
|
August 2, 2013
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma
George Van Buren, Ramesh K Ramanathan, Alyssa M Krasinskas, et al.
Archives of Internal Medicine
|
March 21, 1998
The relationship between cardiothoracic ratio and left ventricular ejection fraction in congestive heart failure. Digitalis Investigation Group
E F Philbin, R Garg, K Danisa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik, Glen J Weiss, John E Leonard, et al.
Investigational New Drugs
|
December 14, 2011
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
Glen J Weiss, Manuel Hidalgo, Mitesh J Borad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2010
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741
Howard L McLeod, Daniel J Sargent, Sharon Marsh, et al.
British Journal of Cancer
|
December 12, 2018
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Cancer Chemotherapy and Pharmacology
|
February 22, 2005
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
Ramesh K Ramanathan, Sakkaraiappan Ramalingam, Merrill J Egorin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2007
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study
Timothy W Synold, Chris H Takimoto, James H Doroshow, et al.
Page
of 31
Search research articles
Search
Showing results (241-250 of 302) with videos related to
Sort By:
Page
of 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
Ramesh K Ramanathan, Merrill J Egorin, Julie L Eiseman, et al.
British Journal of Cancer
|
July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Annals of Surgical Oncology
|
August 2, 2013
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma
George Van Buren, Ramesh K Ramanathan, Alyssa M Krasinskas, et al.
Archives of Internal Medicine
|
March 21, 1998
The relationship between cardiothoracic ratio and left ventricular ejection fraction in congestive heart failure. Digitalis Investigation Group
E F Philbin, R Garg, K Danisa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik, Glen J Weiss, John E Leonard, et al.
Investigational New Drugs
|
December 14, 2011
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
Glen J Weiss, Manuel Hidalgo, Mitesh J Borad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2010
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741
Howard L McLeod, Daniel J Sargent, Sharon Marsh, et al.
British Journal of Cancer
|
December 12, 2018
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Cancer Chemotherapy and Pharmacology
|
February 22, 2005
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
Ramesh K Ramanathan, Sakkaraiappan Ramalingam, Merrill J Egorin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2007
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study
Timothy W Synold, Chris H Takimoto, James H Doroshow, et al.
Page
of 31